Having trouble accessing articles? Reset your cache.

Clavis cancer news

Clavis said it is undergoing a "significant down scaling" of its operations following the discontinued development of elacytarabine to treat acute myelogenous leukemia in April. Clavis said most of the

Read the full 304 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE